Fulcrum Therapeutics (NASDAQ:FULC) Announces Quarterly Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) posted its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03), Zacks reports.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $3.70 on Wednesday. Fulcrum Therapeutics has a 1-year low of $2.86 and a 1-year high of $13.70. The stock has a market cap of $199.57 million, a PE ratio of -11.94 and a beta of 2.03. The firm has a fifty day moving average price of $4.15 and a 200 day moving average price of $4.62.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.